CTOs on the Move

Carta Healthcare

www.carta.healthcare

 
Carta empowers hospitals to personalize the delivery of care to the individual needs of each patient. Our insight here is that personalizing care is not only good from an outcome/clinical perspective (where most people focus in the context of personalization) but is also the best way to optimize operations. Currently, hospitals have to over provision their resources because they are set up to serve the generic patient; planning ahead for exactly the resources needed– no more, no less– is the best way to gain efficiency. The approach we`re advocating and enabling is to: 1) Find past patients similar to the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
James Matheson
Chief Technology Officer Profile

Similar Companies

The Hope Heart Institute

The Hope Heart Institute is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eastern Connecticut Health Network

Eastern Connecticut Health Network, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Eastern Connecticut Health Network, Inc. is based in Manchester, CT. You can find more information on Eastern Connecticut Health Network, Inc. at www.echn.org

ODC Pharma

ODC Pharma is a Woodbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Total e-Medical

Total e-Medical is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Boca Raton, FL. To find more information about Total e-Medical, please visit www.totalemedical.com

ProKidney

ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III